Maria Vaz Pinto

Ms. Maria Vaz Pinto

Neuron-Glia Biology in Health and Disease, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
MSMaria J. S. A. Silva
Maria J. S. A. Silva
HFHélio Faustino
Hélio Faustino
JCJaime Coelho
Jaime Coelho
Maria Vaz PintoMaria Vaz Pinto
Maria Vaz Pinto
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
PGPedro M. P. Gois
Pedro M. P. Gois

Verified
Journal Article
Open access
PDF file
Maria Vaz PintoMaria Vaz Pinto
Maria Vaz Pinto
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
Multiple sclerosis (MS) is the most common autoimmune and demyelinating disease of the central nervous system (CNS), characterized, in the majority of cases, by initial relapses that later evolve into progressive neurodegeneration, severely impacting patients’ motor and cognitive functions. Despite the availability of immunomodulatory therapies effective to reduce relapse rate and slow disease progression, they all failed to restore CNS myelin that is necessary for MS full recovery. Microglia are the primary inflammatory cells present in MS lesions, therefore strongly contributing to demyelination and lesion extension. Thus, many microglial-based therapeutic strategies have been focused on the suppression of microglial pro-inflammatory phenotype and neurodegenerative state to reduce disease severity. On the other hand, the contribution of myelin phagocytosis advocating the neuroprotective role of microglia in MS has been less explored. Indeed, despite the presence of functional oligodendrocyte precursor cells (OPCs), within lesioned areas, MS plaques fail to remyelinate as a result of the over-accumulation of myelin-toxic debris that must be cleared away by microglia. Dysregulation of this process has been associated with the impaired neuronal recovery and deficient remyelination. In line with this, here we provide a comprehensive review of microglial myelin phagocytosis and its involvement in MS development and repair. Alongside, we discuss the potential of phagocytic-mediated therapeutic approaches and encourage their modulation as a novel and rational approach to ameliorate MS-associated pathology.

25 May 2020 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
FSFábio F. M. F. Santos
Fábio F. M. F. Santos
ZDZoe Domínguez
Zoe Domínguez
JFJoão P. L. Fernandes
João P. L. Fernandes
CCCátia Parente Carvalho
Cátia Parente Carvalho
DCDaniel Collado
Daniel Collado
PGPedro M. P. Gois
Pedro M. P. Gois

13 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
Maria Vaz PintoMaria Vaz Pinto
Maria Vaz Pinto
FSFábio M. F. Santos
Fábio M. F. Santos
CBCatarina Barros
Catarina Barros
ARAna Rita Ribeiro
Ana Rita Ribeiro
UPUwe Pischel
Uwe Pischel
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is characterized by the presence of demyelinated regions with accumulated myelin lipid debris. Importantly, to allow effective remyelination, such debris must be cleared by microglia. Therefore, the study of microglial activity with sensitive tools is of great interest to better monitor the MS clinical course. Using a boronic acid-based (BASHY) fluorophore, specific for nonpolar lipid aggregates, we aimed to address BASHY’s ability to label nonpolar myelin debris and image myelin clearance in the context of demyelination. Demyelinated ex vivo organotypic cultures (OCSCs) and primary microglia cells were immunostained to evaluate BASHY’s co-localization with myelin debris and also to evaluate BASHY’s specificity for phagocytosing cells. Additionally, mice induced with experimental autoimmune encephalomyelitis (EAE) were injected with BASHY and posteriorly analyzed to evaluate BASHY+ microglia within demyelinated lesions. Indeed, in our in vitro and ex vivo studies, we showed a significant increase in BASHY labeling in demyelinated OCSCs, mostly co-localized with Iba1-expressing amoeboid/phagocytic microglia. Most importantly, BASHY’s presence was also found within demyelinated areas of EAE mice, essentially co-localizing with lesion-associated Iba1+ cells, evidencing BASHY’s potential for the in vivo bioimaging of myelin clearance and myelin-carrying microglia in regions of active demyelination.

29 January 2021 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
MSMaria J. S. A. Silva
Maria J. S. A. Silva
HFHélio Faustino
Hélio Faustino
JCJaime Coelho
Jaime Coelho
Maria Vaz PintoMaria Vaz Pinto
Maria Vaz Pinto
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
PGPedro M. P. Gois
Pedro M. P. Gois